“Pain is a common symptom of MS, affecting up to 70% of patients.
Pain treatment is often unsatisfactory, although emerging drugs (including cannabinoids) are giving encouraging results.
The aim of our study was to better investigate the role of Sativex® in improving pain in multiple sclerosis (MS) patients by means of either clinical or neurophysiological assessment.
One month of drug administration in MS patients with neuropathic pain successfully reduced pain rating and improved quality of life.
Our data suggest that Sativex may be effective in improving MS-related neuropathic pain, maybe through its action on specific cortical pathways.”